Paradigm Biopharmaceuticals Limited (ASX:PAR)

Australia flag Australia · Delayed Price · Currency is AUD
0.3000
+0.0250 (9.09%)
Apr 24, 2025, 4:10 PM AEST
5.26%
Market Cap 116.83M
Revenue (ttm) 16.70K
Net Income (ttm) -14.56M
Shares Out 389.43M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 685,052
Average Volume 1,125,807
Open 0.2750
Previous Close 0.2750
Day's Range 0.2750 - 0.3050
52-Week Range 0.1650 - 0.6600
Beta 0.62
RSI 40.41
Earnings Date May 28, 2025

About ASX:PAR

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol PAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.